Briacell Awarded National Cancer Institute Grant To Advance Its Bria-OTS Immunotherapy For Cancer; Terms Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
BriaCell Therapeutics Corp. has been awarded a grant by the National Cancer Institute to advance its Bria-OTS immunotherapy for cancer. The terms of the grant were not disclosed.
August 16, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BriaCell Therapeutics Corp. has received a grant from the National Cancer Institute, which could potentially accelerate the development of its Bria-OTS immunotherapy for cancer.
The grant from the National Cancer Institute is a significant endorsement for BriaCell Therapeutics Corp. and its Bria-OTS immunotherapy. This could potentially accelerate the development and approval process of the therapy, which would be a significant positive for the company and could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100